Highlights CanSino Biologics Inc. Shanghai S.E.

Equities

688185

CNE100004BM0

End-of-day quote Shanghai S.E. Other stock markets 18:00:00 2024-06-23 EDT			5-day change	1st Jan Change
42.57 ^CNY	-3.58%		-8.29%	-42.87%

06-24	Cansino Biologics' Senior Management to Boost Stakeholding	MT
06-10	Indonesia ramps up fight against tuberculosis amid concerns on economic impact	RE

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cansino Biologics' Senior Management to Boost Stakeholding	06-24	MT
Cansino Biologics Invests 160 Million Yuan in China Bohai Bank’s Structured Deposits	05-21	MT
CanSino Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-29	CI
Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine	04-22	MT
CanSino Biologics Inc. Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China	04-22	CI
Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results	04-21	MT
Cansino Biologics Begins Phase III Clinical Trials for Tetanus Drug	03-20	MT
Cansino Biologics Inc. Announces Initiation of Phase III Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	03-20	CI
CanSino Biologics Sued by Brazilian Pharma Firm Belcher Over COVID-19 Vaccine Dispute	03-14	MT
Cansino Biologics Inc. Announces Acceptance of Drug Registration Application for 13-Valent Pneumococcal Conjugate Vaccine	02-28	CI
CanSino Biologics' Loss Widens in 2023, Misses EPS, Revenue Estimates; Shares Rise 4%	02-26	MT
CanSino Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-23	CI
CanSino Biologics' Loss to Widen in 2023; Shares Drop 5%	01-31	MT
Cansino Biologics Inc. Provides Earnings Guidance for Year Ended December 31, 2023	01-30	CI
CanSino Biologics Inc. Obtains the Final Report of Phase III Clinical Trial Of 13-Valent Pneumococcal Conjugate Vaccine	01-30	CI
Cansino Biologics Inc. Announces Phase I Clinical Trial and Completion of First Patient Case for Recombinant Poliomyelitis Vaccine	01-15	CI
CanSino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Trial Patient Case for Absorbed Tetanus Vaccine	12-20	CI
Cansino Biologics Inc. Announces Initiation of Phase I Clinical Trial and Completion of First Patient Enrollment for TDCP Adolescent and Adult	12-06	CI
CanSino Biologics' COVID-19 Vaccine Included for China's Emergency Use	12-04	MT
CanSino Biologics Inc. announces Recombinant Covid-19 Xbb.1.5 Variant Vaccine Forinhalation (Adenovirus Type 5 Vector) Included for Emergency Use	12-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

INTERVIEW - Xuefeng Yu, CEO of CanSino Biologics: Behind the scenes of the agreement with AstraZeneca

August 31, 2023 at 06:08 am